ZETAGEN THERAPEUTICS, INC.
Nalovent™ Bone Graft, a combination product that induces bone formation in lytic lesions from breast cancer skeletal metastases
New patent ·
- Sector
- Medtech
- Headquarters
- East Syracuse, NY
- Founded
- 2015
- Latest Form D
- $83K, Jan 2025
- Total capital
- $17.3M
- Federal grants
- $4M
- 6 awards · 2018–2022
- Rank in peer group#218 of 538
- Private capital raised
- $13.3M
- 5 Form D · last Jan 2025
- 21 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 18 pending · first 2022
- Rank in peer group#56 of 538
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$83K
- Private capital raisedForm D · SEC · 4th filing$9.6M
- Federal grantHealth and Human S · Phase II · Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases$985K
- Federal grantHealth and Human S · Phase II · Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases$250K
- Federal grantHealth and Human S · Phase II · Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases$2.2M
- Private capital raisedForm D · SEC · 3rd filing$840K
- Federal grantHealth and Human S · Phase I · Validation of a novel, small molecule-based osteoinductive lumbar fusion implant$225K
- Private capital raisedForm D · SEC · 2nd filing$1M
- Private capital raisedForm D · SEC · 1st filing$1.7M
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase I · Validation of a novel, adjuvant implant for post-metastatic skeletal lesions$2K
- Federal grantHealth and Human S · Phase I · Validation of a novel, adjuvant implant for post-metastatic skeletal lesions$302K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 538 peers
Line = medianMedtech · Device
- Federal grants#218 · top 41%
- Granted patents#56 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ashok C KaveeshwarDirectorNamed in SEC Form D filings
- David B. TischlerExecutive Officer, DirectorNamed in SEC Form D filings
- Donald C BrownDirectorNamed in SEC Form D filings
- Joe C LoyExecutive Officer, DirectorNamed in SEC Form D filings
- Nikhil Thakur, MDExecutive Officer, DirectorNamed in SEC Form D filings
- Peter B. FinnExecutive OfficerNamed in SEC Form D filings
Show all 7 people
- Richard C WarburgDirectorNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 29- New patentPolysilane Methacrylic Compounds, Methods Of Making Them And Their Uses, Including For The Treatment Of CancerUSPTOUS 12,766,165
- PendingCancer Treatments Using Modified Fatty Acids And The Carriers To Administer ThemUSPTOApplication 19236191
- PendingLanthanum Compositions For Treating CancerUSPTOApplication 19405165
Show all 29 patent records
- Polysilane Methacrylic Compounds, Methods Of Making Them And Their Uses, Including For The Treatment Of CancerOct 20, 2026 · US 12,766,165Granted
- Cancer Treatments Using Modified Fatty Acids And The Carriers To Administer ThemSep 10, 2026 · Application 19236191Pending
- Lanthanum Compositions For Treating CancerJun 4, 2026 · Application 19405165Pending
- Compositions Using Iron Excipients And Their Uses Including For The Treatment Of CancerNov 20, 2025 · Application 19280749Pending
- Cancer Treatments Using Modified Fatty Acids And The Carriers To Administer ThemSep 2, 2025 · US 12,403,118Granted
- Compositions Using Iron Excipients And Their Uses Including For The Treatment Of CancerAug 19, 2025 · US 12,390,551Granted
- Polysilane Methacrylic Compounds, Methods Of Making Them And Their Uses, Including For The Treatment Of CancerAug 7, 2025 · Application 18888673Pending
- Methods And Compositions For Treating CancerMay 27, 2025 · US 12,310,962Granted
- Methods Of Treating Prostate Cancer Or Metastasized Prostate CancerFeb 13, 2025 · Application 18366439Pending
- Polysilane Methacrylic Compounds And Methods Of Making ThemDec 24, 2024 · US 12,171,780Granted
- Polysilane Methacrylic Compounds And Methods Of Making ThemOct 29, 2024 · US 12,128,064Granted
- Polysilane Methacrylic Compounds And Methods Of Making ThemOct 8, 2024 · US 12,109,226Granted
- Controlled Release Formulation And Minimally Invasive Method Of AdministrationSep 17, 2024 · US 12,090,152Granted
- Methods And Compositions For Treating CancerMay 14, 2024 · US 11,980,615Granted
- Controlled Release Formulation And Minimally Invasive Method Of Administration To Locally Treat CancerApr 16, 2024 · US 11,957,676Granted
- Methods And Compositions To Graft Bone Using Iron ExcipientsJan 4, 2024 · Application 18463056Pending
- Methods And Compositions For Treating CancerOct 18, 2022 · US 11,471,454Granted
- Methods And Compositions To Graft Bone Using Iron Excipients For Cancer TreatmentJan 20, 2022 · Application 17143468Pending
- Methods And Compositions For Treating CancerFeb 4, 2021 · Application 16928830Pending
- Methods And Compositions To Graft Bone Using Iron ExcipientsApplication 63053277Pending
- Cancer Treatments Using Modified Fatty Acids And The Carriers To Administer ThemApplication PCTUS2026017630Pending
- Polysilane Methacrylic Compounds And Methods Of Making ThemApplication PCTUS2025014401Pending
- Controlled Release Formulation And Minimally Invasive Method Of AdministrationApplication 19509166Pending
- Trisilane Methacrylic Compounds And Methods Of Making ThemApplication 63549854Pending
- Lanthanum Compositions For Treating CancerApplication PCTUS2025057449Pending
- Lanthanum Compositions For Treating CancerApplication 63726990Pending
- Controlled Release Formulation And Minimally Invasive Method Of AdministrationApplication PCTUS2024041030Pending
- Formulations Of Opioid Growth Factor Receptor Antagonist And Methods Of TreatmentApplication PCTUS2024041033Pending
- Methods And Compositions To Graft Bone Using Iron ExcipientsApplication PCTUS2021012445Pending
Related companies, and why
- CALVIRI, INC.Similar federal contract value in Medtech · null in contracts
- IVIEW Therapeutics IncSimilar federal contract value in Medtech · null in contracts
- SENTIAR, INC.Similar federal contract value in Medtech · null in contracts
- Harpoon Medical, Inc.Similar federal contract value in Medtech · null in contracts
- VASOPTIC MEDICAL, INC.Similar federal contract value in Medtech · null in contracts
- Nupulsecv IncSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .